High Throughput Mass Spectrometry Services for Untargeted Biomarker Profiling

Much like the way next-generation sequencing greatly accelerated discovery of disease-associated genetic variants in the last decade, Sapient next-generation mass spectrometry platform is transforming discovery metabolomics, allowing us to peer deeper into the chemical realm than ever before possible. We use these technologies to map small molecule biomarkers at scale, and they provide our sponsor partners with enormous potential to help better understand disease and address longstanding drug development challenges.

Our rapid liquid chromatography-mass spectrometry (rLC-MS) systems enable ultra high throughput, nontargeted capture and measure of >11,000 small molecule biomarkers across broad chemical classes, in <1 minute analytical cycle time. This gives us the capacity to assay thousands of samples at a time, delivering the population-level insights sponsors need for better decision making in the drug development process. You can see the range of chemistries captured in this infographic.

These high throughput mass spectrometry systems are embedded in a larger discovery pipeline which includes biocomputational integration for spectral data and multi-omics analysis, as well as biological validation of key identified biomarkers using Sapient’s Human Biology Database – encompassing data from >100,000s of human biosamples already run through untargeted discovery screenings using our next-gen mass specs.

Learn more about our high throughput mass spectrometry systems for large-scale biomarker profiling. Use the form to download our technical fact sheet or schedule a time to talk to our scientists here.